Targeted therapies in early-stage breast cancer

Achievements and promises

George W. Sledge, Aparna C. Jotwani, Lida Mina

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2)-targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti-vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple-negative breast cancers, and agents targeting site-specific metastasis to the bone (receptor activator of NF-kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.

Original languageEnglish
Pages (from-to)669-679
Number of pages11
JournalSurgical Oncology Clinics of North America
Volume19
Issue number3
DOIs
StatePublished - Jul 2010

Fingerprint

Breast Neoplasms
Therapeutics
Triple Negative Breast Neoplasms
Poly(ADP-ribose) Polymerases
NF-kappa B
Vascular Endothelial Growth Factor A
Neoplasm Metastasis
Ligands
Bone and Bones
Drug Therapy

Keywords

  • Breast cancer
  • Chemotherapy
  • HER2
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Targeted therapies in early-stage breast cancer : Achievements and promises. / Sledge, George W.; Jotwani, Aparna C.; Mina, Lida.

In: Surgical Oncology Clinics of North America, Vol. 19, No. 3, 07.2010, p. 669-679.

Research output: Contribution to journalArticle

Sledge, George W. ; Jotwani, Aparna C. ; Mina, Lida. / Targeted therapies in early-stage breast cancer : Achievements and promises. In: Surgical Oncology Clinics of North America. 2010 ; Vol. 19, No. 3. pp. 669-679.
@article{1e578265181244c194ab0cd8fd349fb1,
title = "Targeted therapies in early-stage breast cancer: Achievements and promises",
abstract = "One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2)-targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti-vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple-negative breast cancers, and agents targeting site-specific metastasis to the bone (receptor activator of NF-kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.",
keywords = "Breast cancer, Chemotherapy, HER2, Targeted therapy",
author = "Sledge, {George W.} and Jotwani, {Aparna C.} and Lida Mina",
year = "2010",
month = "7",
doi = "10.1016/j.soc.2010.04.005",
language = "English",
volume = "19",
pages = "669--679",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Targeted therapies in early-stage breast cancer

T2 - Achievements and promises

AU - Sledge, George W.

AU - Jotwani, Aparna C.

AU - Mina, Lida

PY - 2010/7

Y1 - 2010/7

N2 - One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2)-targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti-vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple-negative breast cancers, and agents targeting site-specific metastasis to the bone (receptor activator of NF-kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.

AB - One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2)-targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti-vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple-negative breast cancers, and agents targeting site-specific metastasis to the bone (receptor activator of NF-kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.

KW - Breast cancer

KW - Chemotherapy

KW - HER2

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77954159097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954159097&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2010.04.005

DO - 10.1016/j.soc.2010.04.005

M3 - Article

VL - 19

SP - 669

EP - 679

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 3

ER -